30742-62-2

Usage

Uses

Used in Pharmaceutical Industry:
2-morpholino-5-nitrobenzaldehyde is used as a synthetic intermediate for the production of various pharmaceuticals. Its chemical reactivity, stemming from the nitro and aldehyde groups, facilitates the synthesis of a range of medicinal compounds, contributing to the development of new drugs and therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, 2-morpholino-5-nitrobenzaldehyde is utilized as a key component in the synthesis of complex organic molecules. Its ability to undergo reduction and condensation reactions makes it a valuable building block for the creation of diverse organic compounds with potential applications in various industries.
Used in Dye and Pigment Production:
2-morpholino-5-nitrobenzaldehyde is used as a precursor in the production of dyes and pigments. Its aromatic structure and capacity to form complex molecules make it suitable for creating a variety of colorants used in different applications, such as textiles, plastics, and printing inks.
Used in Research and Development:
In research settings, 2-morpholino-5-nitrobenzaldehyde serves as a model compound for studying chemical reactions and exploring new synthetic pathways. Its reactivity and structural features make it an interesting subject for scientific investigations, potentially leading to the discovery of novel compounds and applications.

InChI:InChI=1/C11H12N2O4/c14-8-9-7-10(13(15)16)1-2-11(9)12-3-5-17-6-4-12/h1-2,7-8H,3-6H2

Upstream product

• 110-91-8 morpholine 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 

Downstream Products

• 30742-77-9 bis-(2-morpholin-4-yl-5-nitro-benzylidene)-hydrazine 
• 30742-68-8 2-morpholin-4-yl-5-nitro-benzaldehyde (toluene-4-sulfonyl)-hydrazone 
• 296244-43-4 1,3-dimethyl-5-(2-morpholino-5-nitrobenzylidene)hexahydropyrimidine-2,4,6-trione 
• 1093798-66-3 N-methyl-1-(2-morpholino-5-nitrophenyl)methanamine 
• 1093798-67-4 C₁₈H₂₇N₃O₅ 
• 959755-61-4 (5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)-[3-(tert-butyl-dimethyl-silanyloxymethyl)-4-morpholin-4-yl-phenyl]-amine 
• 959755-64-7 [5-(5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamino)-2-morpholin-4-yl-phenyl]-methanol 
• 957346-19-9 3-(tert-butyl-dimethyl-silanyloxymethyl)-4-morpholin-4-yl-phenylamine 
• 759456-60-5 (5-amino-2-morpholinophenyl)methanol 

Relevant academic research and scientific papers

PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS

The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds i

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27) ,9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer

Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27) ,16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2 V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2 WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.

Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst

"One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product

Synthesis of spiroheterocyclic systems from barbituric acids and N,N-disubstituted o-aminobenzaldehydes

Reactions of barbituric, 1,3-dimethylbarbituric, and 2-thiobarbituric acids with 2-(1-pyrrolidinyl)benzaldehyde, its 6- and 7-membered homologs, and 4-phenylpiperazine and morpholine analogs lead to formation of fused systems with a spirocyclic 2,4,6-trio

TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS

The invention includes tetrahydroquinoline and related compounds of formula (I), and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.